42,385 Shares in Teva Pharmaceutical Industries Ltd. $TEVA Purchased by WealthTrust Asset Management LLC

WealthTrust Asset Management LLC bought a new stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 42,385 shares of the company’s stock, valued at approximately $856,000.

A number of other large investors have also added to or reduced their stakes in TEVA. AQR Capital Management LLC lifted its stake in Teva Pharmaceutical Industries by 24.6% in the first quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock valued at $368,000 after purchasing an additional 4,732 shares during the last quarter. Focus Partners Wealth boosted its holdings in Teva Pharmaceutical Industries by 4.5% in the 1st quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock valued at $616,000 after purchasing an additional 1,739 shares during the period. CWM LLC grew its position in Teva Pharmaceutical Industries by 18.1% during the second quarter. CWM LLC now owns 4,995 shares of the company’s stock worth $84,000 after buying an additional 767 shares in the last quarter. Transcend Capital Advisors LLC raised its stake in Teva Pharmaceutical Industries by 7.6% in the second quarter. Transcend Capital Advisors LLC now owns 13,692 shares of the company’s stock valued at $229,000 after purchasing an additional 973 shares in the last quarter. Finally, Hantz Financial Services Inc. lifted its holdings in shares of Teva Pharmaceutical Industries by 1,351.1% during the 2nd quarter. Hantz Financial Services Inc. now owns 6,138 shares of the company’s stock worth $103,000 after acquiring an additional 5,715 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Trading Up 0.2%

TEVA stock opened at $33.85 on Friday. Teva Pharmaceutical Industries Ltd. has a 12 month low of $12.47 and a 12 month high of $37.35. The company has a market capitalization of $38.92 billion, a PE ratio of 28.21, a P/E/G ratio of 11.30 and a beta of 0.70. The firm’s 50-day moving average is $32.94 and its 200 day moving average is $25.68. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.04 and a quick ratio of 0.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The company had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.36 billion. During the same period last year, the company posted $0.71 earnings per share. Teva Pharmaceutical Industries’s revenue was up 11.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently commented on TEVA. Piper Sandler increased their target price on shares of Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the company an “overweight” rating in a report on Monday, December 22nd. The Goldman Sachs Group increased their price objective on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Scotiabank upped their price target on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a research note on Thursday, January 29th. Truist Financial lifted their price objective on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Finally, Bank of America raised their price objective on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.56.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, VP Richard Daniell sold 115,468 shares of the company’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $28.68, for a total transaction of $3,311,622.24. Following the transaction, the vice president owned 48,384 shares in the company, valued at approximately $1,387,653.12. This represents a 70.47% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Roberto Mignone sold 77,400 shares of the company’s stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $30.24, for a total value of $2,340,576.00. Following the completion of the sale, the director owned 367,600 shares in the company, valued at approximately $11,116,224. This represents a 17.39% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 422,060 shares of company stock worth $12,254,965 in the last quarter. 0.49% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.